AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
The following are summaries of selected poster presentations from the AAGP 2009 Annual Meeting, held in Honolulu, Hawaii, March 5-9, 2009. Posters represent preliminary research.
Adjunctive dronabinol reduces agitation/aggression in dementia
Adjunctive dronabinol, a cannabinoid receptor agonist, significantly reduced agitation/ aggression and improved sleep in patients with moderate to severe dementia, according to a retrospective chart review. Although dronabinol has been shown to increase appetite, the current review found no significant association between dronabinol treatment and changes in body weight or food intake. The review was based on medical records of all 41 patients (mean age 81 years; 73% male) admitted to the Geriatric Neuropsychiatry Unit of McLean Hospital, Belmont, Massachusetts, between August 1, 2006 and May 31, 2008. The mean duration of dronabinol treatment was 14 days. Doses ranged from 2.5 to 20 mg, with the …